预防性艾斯凯胺来减少primiparae产后抑郁症:一个多中心,双盲,随机的临床试验
Tiantian Chu1, Xiaoling Peng, Keliang Wan
1From the Department of Anaesthesiology, Hubei Key Laboratory of Geriatric Anaesthesia and Peri-operative Brain Health, and Wuhan Clinical Research Centre for Geriatric Anaesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (TC, XP, KW, ML, TL, XS, WY, SL, ZZ, AL, AX, FG), Department of Anaesthesiology, Jingmen Central Hospital affiliated to Jingchu University of Technology, Jingmen (CY, JK, CW), Department of Anaesthesiology, Maternal and Child Health Hospital of Hubei Province, Wuhan (HX, JC, ZX), Department of Anaesthesiology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou (DL), Department of Anaesthesiology, the People's Hospital of Hanchuan, Hanchuan (XL), Department of Anaesthesiology, the People's Hospital of Jingmen, Jingmen (JH) and Department of Anaesthesiology & Institute of Neuroscience and Brain Diseases, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China (XY).
在7天内,预防性胺剂的使用显著降低了第一次母亲的产后抑郁症 (PPD) 发生率. 虽然短期内安全,但其长期的PPD预防效果需要进一步调查.
科学领域:
- 产科和妇科 产科和妇科
- 麻醉学 麻醉学
- 精神病学是一个精神病学.
背景情况:
- 产后抑郁症 (PPD) 影响了许多女性,尤其是第一次成为母亲的女性.
- 确定有效的PPD预防策略对于母亲的福祉至关重要.
研究的目的:
- 为了评估预防性埃斯基坦胺在预防PPD中的有效性,在没有产前抑郁症的Primiparae中.
- 评估手术前期治疗中用于预防PPD的esketamine的安全性和短期有效性.
主要方法:
- 一项前性,双盲,随机对照试验,涉及322名接受选择性剖腹产的初级患者.
- 参与者接受了胺或盐水作为预防措施.
- 主要结局是产后3个月内PPD发生率;次要结局包括EPDS得分和不良事件.
主要成果:
- 在产后7天以后,sketamine显著降低了PPD发病率 (11.59%对比20.89%).
- 在产后1,2或3个月后,没有观察到PPD发病率或EPDS得分的显著差异.
- 在埃斯基坦胺治疗期间,观察到轻微的中枢神经系统副作用,如头和幻觉.
结论:
- 外科期间使用的埃斯基坦胺是一种相对安全的辅助治疗方法.
- 素可以在短期内预防PPD对于没有产前抑郁症的primiparae.
- 需要进一步的研究来确定长期PPD预防的有效性.
相关概念视频
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Blind Procedures
Statistical Software for Data Analysis and Clinical Trials
Blinding
Long-term Depression


